Replies to post #216976 on Biotech Values

[DewDiligence]

p.s. GEMP needs a better name for its NAFLD/NASH drug, Gemcabene—it sounds too much like Gemcitabine.

[DewDiligence]

GEMP—(-23%)—sells 3.61M* shares@$7.00—a 21% discount to yesterday’s close:

https://finance.yahoo.com/news/gemphire-announces-pricing-22-million-140000490.html

GEMP is encountering some headwind in its attempt to be taken seriously as a NASH company.

*Assuming exercise of underwriter’s option.